Soligenix, Inc. Files 8-K Report

Ticker: SNGX · Form: 8-K · Filed: Apr 3, 2024 · CIK: 812796

Soligenix, Inc. 8-K Filing Summary
FieldDetail
CompanySoligenix, Inc. (SNGX)
Form Type8-K
Filed DateApr 3, 2024
Risk Levellow
Pages3
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting

Related Tickers: SOLI

TL;DR

SOLI filed an 8-K, looks like standard financial reporting, no major news.

AI Summary

On April 3, 2024, Soligenix, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a major event. No specific financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing indicates Soligenix, Inc. is meeting its reporting obligations with the SEC, which is standard for publicly traded companies. It suggests no immediate, significant operational changes or financial events are being disclosed at this time.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, with no indication of significant negative events or material changes.

Key Players & Entities

  • Soligenix, Inc. (company) — Filer of the 8-K report
  • April 3, 2024 (date) — Date of the report
  • 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 (address) — Principal executive offices

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not specify which ones.

Does this 8-K report disclose any new material events for Soligenix, Inc.?

The excerpt lists 'Other Events' and 'Financial Statements and Exhibits' as item information, suggesting routine reporting rather than a specific new material event.

What is the principal business address of Soligenix, Inc.?

The principal executive offices are located at 29 Emmons Drive, Suite B-10, Princeton, NJ 08540.

When was Soligenix, Inc. incorporated or organized?

The company is incorporated in Delaware.

What is the Commission File Number for Soligenix, Inc.'s SEC filings?

The Commission File Number is 001-14778.

Filing Stats: 813 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-04-03 16:05:34

Filing Documents

01. Other Events

Item 8.01. Other Events. On April 3, 2024, Soligenix, Inc. (the "Company") issued a press release announcing the receipt of agreement from the European Medicines Agency on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma patients with early-stage disease. This confirmatory 18-week study is expected to enroll approximately 80 patients in the United States and Europe and is targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The Company updated its corporate presentation (the "Presentation") as of April 3, 2024 to incorporate information relating to the confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte in the treatment of cutaneous T-cell lymphoma patients with early-stage disease. The slides from the Presentation are attached hereto as Exhibit 99.2. The Presentation also will be posted on the Company's website at www.soligenix.com. Safe Harbor for Forward-Looking Statements Certain statements contained in this report may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the 1934 Act. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "predicts," "plans," "expects," "anticipates," "believes," "goal," "target," "estimate," "potential," "may," "might," "could," "see," "seek," "forecast," and similar words. Forward-looking statements are based on the Company's current plans and expectations and involve risks and uncertainties which are, in many instances, beyond the Company's control, and which could cause actual re

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 3, 2024 99.2 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Soligenix, Inc. April 3, 2024 By: /s/ Christopher J. Schaber Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.